Company profile
Novo Nordisk A/S
New York Stock Exchange (ticker: NVO); Nasdaq Copenhagen (local listings, including B-shares):NVO · Pharmaceuticals / Drug Manufacturers - General
Novo Nordisk A/S is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsværd, Denmark. The company researches, develops and markets medicines and devices primarily for diabetes and obesity care, and also operates in haemostasis, growth disorders and hormone replacement therapies.
Market Cap
$163.8B
P/E
10.4
Revenue (TTM)
$309.1B
Exchange
New York Stock Exchange (ticker: NVO); Nasdaq Copenhagen (local listings, including B-shares)
Team
Team
MD
Maziar Mike (Mike) Doustdar
President & Chief Executive Officer (CEO)
KK
Karsten Munk Knudsen
Executive Vice President & Chief Financial Officer (CFO)
ML
Martin Holst Lange
Executive Vice President, R&D and Chief Scientific Officer (CSO)
LS
Lars Rebien Sørensen
Chairman of the Board
